Table 3. Anticoagulation control as assessed by percent time in target range (PTTR; INR 2-3) by CYP4F2 genotype.
| Parameter | CYP4F2 *1/*1 | CYP4F2 *1/*3 | CYP4F2 *3/*3 | P Value | |
|---|---|---|---|---|---|
| Number of patients | 784 | 390 | 64 | ||
| Number of visits | 21008 | 10420 | 1864 | ||
| Follow-up (months) | 13193 | 6643 | 1289 | ||
| Follow-up months/patient | 16.8 ± 10.6 | 17.0 ± 10.8 | 20.1 ± 10.4 | 0.06 | |
|
| |||||
| Distribution of treatment time spent below range, in range and above range | |||||
|
| |||||
| PTBR | 29.6 | 26.2 | 26.0 | 0.09 | |
| PTTR | 52.5 | 57.1 | 56.4 | 0.002 | |
| PTAR | 17.9 | 16.7 | 17.6 | 0.57 | |
|
| |||||
|
Distribution of treatment time spent below range, in range and above range after controlling
for confoundersa | |||||
|
| |||||
| PTBR | 28.6 | 27.5 | 29.4 | 0.77 | |
| PTTR | 53.5 | 55.5 | 53.8 | 0.34 | |
| PTAR | 17.9 | 17.0 | 16.8 | 0.73 | |
INR: International Normalized Ratio
PTBR denotes percent time spent below range (INR 2-3); PTTR denotes percent time spent in range (INR 2-3); PTAR denotes percent time spent above range (INR 2-3)
a
Adjusted analysis includes age, race, BSA, current smoking, chronic kidney disease, concurrent statin and antiplatelet use, CYP2C9, and VKORC1 variants